LATEST HEADLINES

60P received Priority Review Designation from the USFDA for Tafenoquine (TQ) for prevention of malaria in adults. Learn More

Developing therapeutic innovations that can significantly improve and extend people’s lives.

In 2010, 60° Pharmaceuticals began its mission to build a better world by undertaking research and action focused on aiding in the prevention of tropical diseases.

Escalating malaria care
to people in need around
the world

Advancing therapies for the treatment and prevention of malaria.

Meeting the challenges of
the global dengue endemic

With no commercially available drugs or vaccines to effectively combat dengue, 60P is poised to enter this treatment arena.

For the investment community

We are committed to serving the best interests of our investors.

CAREERS

Our team is committed to creating innovative, potentially lifesaving medicines to significantly impact the quality of life for those affected by tropical diseases worldwide.

429,000

Deaths annually in endemic countries from malaria

125,000,000

Travelers to endemic regions per annum

390,000,000

Dengue infections per year

202-327-5422

1025 Connecticut Ave. NW, Suite 1000, Washington, DC 20036